|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6664227B1
(en)
*
|
1996-03-01 |
2003-12-16 |
Genetics Institute, Llc |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
|
|
EP0812913A3
(en)
*
|
1996-06-12 |
1999-08-04 |
Smithkline Beecham Corporation |
HR-1 receptor, a receptor of the cytokine receptors family
|
|
US5986059A
(en)
|
1996-06-14 |
1999-11-16 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6335426B1
(en)
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
US6287801B1
(en)
*
|
1996-07-22 |
2001-09-11 |
Smithkline Beecham Corporation |
Nucleic acids encoding the G-protein coupled receptor HNFDS78
|
|
JP4175668B2
(ja)
*
|
1996-12-20 |
2008-11-05 |
アムジエン・インコーポレーテツド |
Ｏｂ融合タンパク質組成物および方法
|
|
US6852508B1
(en)
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
|
US6100387A
(en)
*
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
|
JP2002506625A
(ja)
|
1998-03-19 |
2002-03-05 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
サイトカインレセプター共通γ鎖様
|
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
US20010021380A1
(en)
*
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
|
ES2609016T3
(es)
|
2000-06-16 |
2017-04-18 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a BLyS
|
|
CA2430039C
(en)
|
2000-11-28 |
2014-01-28 |
Medimmune, Inc. |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
|
EP2357187A1
(en)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
|
US7094892B2
(en)
*
|
2001-02-22 |
2006-08-22 |
The Research Foundation Of State University Of New York |
Nucleic acids encoding opiate receptors
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
血管内皮増殖因子２
|
|
US7064189B2
(en)
|
2001-05-25 |
2006-06-20 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
|
WO2004014292A2
(en)
|
2002-05-10 |
2004-02-19 |
Purdue Research Foundation |
EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
BRPI0406776A
(pt)
*
|
2003-01-18 |
2005-12-27 |
Childrens Hosp Medical Center |
Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
DE602004027888D1
(de)
|
2003-02-20 |
2010-08-12 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihr
|
|
DE602004025332D1
(de)
|
2003-03-14 |
2010-03-18 |
Wyeth Corp |
Antikörper gegen il21-rezeptor und deren verwendung
|
|
ES2391087T3
(es)
|
2003-04-11 |
2012-11-21 |
Medimmune, Llc |
Anticuerpos de IL-9 recombinantes y usos de los mismos
|
|
NZ543292A
(en)
*
|
2003-06-12 |
2008-04-30 |
Lilly Co Eli |
GLP-1 analog fusion proteins
|
|
CA2526169A1
(en)
*
|
2003-06-12 |
2004-12-23 |
Eli Lilly And Company |
Fusion proteins
|
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
|
US8420087B2
(en)
|
2004-01-05 |
2013-04-16 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
EP1786463A4
(en)
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
ANTIBODY AGAINST NOGO RECEPTOR
|
|
US7576190B2
(en)
|
2004-05-13 |
2009-08-18 |
Eli Lilly And Company |
FGF-21 fusion proteins
|
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
EP3073267A1
(en)
|
2004-09-21 |
2016-09-28 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
|
PT1831252E
(pt)
*
|
2004-12-22 |
2009-09-17 |
Lilly Co Eli |
Formulações de proteínas de fusão de análogos de glp-1
|
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
|
BRPI0611069A2
(pt)
|
2005-05-06 |
2010-11-09 |
Zymogenetics Inc |
anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
|
|
JP2008546805A
(ja)
|
2005-06-23 |
2008-12-25 |
メディミューン，エルエルシー |
最適な凝集および断片化プロフィールを有する抗体製剤
|
|
WO2007056352A2
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
|
CA2650730A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
ATE520032T1
(de)
|
2006-06-21 |
2011-08-15 |
Apogenix Gmbh |
Differentielle cytokinexpression bei einer menschlichen krebserkrankung
|
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
TW201343676A
(zh)
|
2006-08-28 |
2013-11-01 |
Kyowa Hakko Kirin Co Ltd |
具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
|
|
ES2548714T3
(es)
|
2006-09-01 |
2015-10-20 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y procedimientos de uso
|
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
|
CA2699837C
(en)
|
2006-12-01 |
2017-06-13 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
EP2077859A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
ANTIBODY FORMULATION
|
|
SG194368A1
(en)
|
2007-05-04 |
2013-11-29 |
Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
|
RU2519227C2
(ru)
|
2007-05-14 |
2014-06-10 |
Медиммун, Ллк |
Способы снижения числа эозинофилов
|
|
PT2796466T
(pt)
|
2007-12-07 |
2018-02-23 |
Zymogenetics Inc |
Moléculas de anticorpo humanizado específicas para il-31
|
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
|
EP2282773B1
(en)
|
2008-05-02 |
2014-01-15 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
KR101030978B1
(ko)
*
|
2008-07-10 |
2011-04-28 |
(주) 에이프로젠 |
동물세포용 재조합 발현벡터
|
|
ES2541142T3
(es)
|
2008-08-05 |
2015-07-16 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos contra la proteína C5 del complemento
|
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
|
EP2421896A1
(en)
|
2009-04-22 |
2012-02-29 |
Merck Patent GmbH |
Antibody fusion proteins with modified fcrn binding sites
|
|
US20120134984A1
(en)
|
2009-06-01 |
2012-05-31 |
Olga Lubman |
Molecules with extended half-lives and uses thereof
|
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
|
EP3659596A1
(en)
|
2009-07-20 |
2020-06-03 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with paclitaxel for the synergistic treatment of proliferative diseases
|
|
US9133500B2
(en)
|
2009-08-10 |
2015-09-15 |
MorphoSys A6 |
Screening strategies for the identification of binders
|
|
AU2010282340B2
(en)
|
2009-08-13 |
2016-12-22 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
JP2013527762A
(ja)
|
2010-05-06 |
2013-07-04 |
ノバルティス アーゲー |
治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
|
|
CA2798390A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
MX356527B
(es)
|
2010-07-09 |
2018-06-01 |
Bioverativ Therapeutics Inc |
Polipeptidos de factor ix y metodos para usarlos.
|
|
BR112012031638B1
(pt)
|
2010-07-09 |
2021-01-12 |
Janssen Vaccines & Prevention B.V. |
anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
|
AU2011293127B2
(en)
|
2010-08-27 |
2016-05-12 |
Abbvie Stemcentrx Llc |
Notum protein modulators and methods of use
|
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス，インコーポレイテッド |
Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
WO2012078813A2
(en)
|
2010-12-08 |
2012-06-14 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
|
MX358862B
(es)
|
2011-11-04 |
2018-09-06 |
Zymeworks Inc |
Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
|
|
WO2013067355A1
(en)
|
2011-11-04 |
2013-05-10 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
|
US9453073B2
(en)
|
2011-12-02 |
2016-09-27 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
BR112014013412A8
(pt)
|
2011-12-05 |
2021-06-08 |
Novartis Ag |
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos
|
|
EP3330288A1
(en)
|
2011-12-21 |
2018-06-06 |
Novartis AG |
Compositions and methods for antibodies targeting factor p
|
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
EP3539985A1
(en)
|
2012-02-24 |
2019-09-18 |
AbbVie Stemcentrx LLC |
Anti sez6 antibodies and methods of use
|
|
SG11201405131XA
(en)
|
2012-02-24 |
2014-10-30 |
Stemcentrx Inc |
Dll3 modulators and methods of use
|
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2014018625A1
(en)
|
2012-07-25 |
2014-01-30 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
EP2906598A1
(en)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
SI2928921T1
(sl)
|
2012-12-05 |
2021-05-31 |
Novartis Ag |
Sestavki in postopki za protitelesa, ki ciljajo epo
|
|
MX2015007931A
(es)
|
2012-12-18 |
2015-10-05 |
Novartis Ag |
Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
|
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Ｎｏｔｃｈ３に対する抗体
|
|
ME02917B
(me)
|
2013-03-14 |
2018-10-20 |
Bristol Myers Squibb Co |
Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene
|
|
CN103265637B
(zh)
*
|
2013-06-04 |
2015-10-21 |
江苏众红生物工程创药研究院有限公司 |
一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法
|
|
SG11201509982UA
(es)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
RS62189B1
(sr)
|
2013-08-26 |
2021-08-31 |
Biontech Research And Development Inc |
Nukleinske kiseline koje kodiraju humana antitela na sijalil-luis a
|
|
SG11201601416VA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Novel sez6 modulators and methods of use
|
|
MX2016002547A
(es)
|
2013-08-28 |
2016-06-17 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
|
|
EP3065780A1
(en)
|
2013-11-04 |
2016-09-14 |
Pfizer Inc. |
Anti-efna4 antibody-drug conjugates
|
|
RU2701434C2
(ru)
|
2014-01-24 |
2019-09-26 |
Нгм Биофармасьютикалс, Инк. |
Связывающие белки и способы их применения
|
|
CR20160437A
(es)
|
2014-02-21 |
2017-02-20 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9546214B2
(en)
|
2014-04-04 |
2017-01-17 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
|
JP7179400B2
(ja)
|
2014-05-13 |
2022-11-29 |
バイオアトラ インコーポレイテッド |
条件的活性型生物学的タンパク質
|
|
ES2869459T3
(es)
|
2014-05-16 |
2021-10-25 |
Medimmune Llc |
Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
|
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
|
BR112017004131A2
(pt)
|
2014-09-03 |
2017-12-12 |
Bioatla Llc |
método de produção de uma proteína biológica condicionalmente ativa, proteína biológica condicionalmente ativa, receptor de antígeno quimérico, e, célula citotóxica.
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
HUE061070T2
(hu)
|
2015-03-03 |
2023-05-28 |
Kymab Ltd |
Ellenanyagok, alkalmazások és eljárások
|
|
KR20180014714A
(ko)
|
2015-06-05 |
2018-02-09 |
노파르티스 아게 |
골 형태형성 단백질 9 (bmp9)를 표적화하는 항체 및 그에 대한 방법
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Ｆｇｆ２１関連障害を処置する方法
|
|
LT3347377T
(lt)
|
2015-09-09 |
2021-05-25 |
Novartis Ag |
Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai
|
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
|
KR20180064534A
(ko)
|
2015-11-02 |
2018-06-14 |
바이오아트라, 엘엘씨 |
조건부 활성 폴리펩티드
|
|
WO2017093947A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子１５に対する抗体およびそれらの使用
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
|
EP3481866A1
(en)
|
2016-07-06 |
2019-05-15 |
Bristol-Myers Squibb Company |
Combination of tim-4 antagonist and pd-1 antagonist and methods of use
|
|
SG11201901950TA
(en)
|
2016-09-19 |
2019-04-29 |
Celgene Corp |
Methods of treating immune disorders using pd-1 binding proteins
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
|
JP7110199B2
(ja)
|
2016-12-23 |
2022-08-01 |
ノバルティス アーゲー |
抗第ＸＩ／ＸＩａ因子抗体による処置法
|
|
JP6991246B2
(ja)
|
2017-02-08 |
2022-02-03 |
ノバルティス アーゲー |
Ｆｇｆ２１模倣抗体及びその使用
|
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3694889A1
(en)
|
2017-10-13 |
2020-08-19 |
Boehringer Ingelheim International GmbH |
Human antibodies to thomsen-nouvelle (tn) antigen
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
CR20200571A
(es)
|
2018-06-01 |
2021-01-18 |
Novartis Ag |
Moléculas de únion contra bcma y usos de las mismas
|
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ， インコーポレイテッド |
高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
|
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
|
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
WO2024094755A1
(en)
*
|
2022-11-02 |
2024-05-10 |
Synerkine Pharma B.V. |
Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
|